Skip to content. | Skip to navigation

Personal tools
Log in
Sections
Home > Profiles > Tanyel Kiziltepe

Tanyel Kiziltepe

Tanyel Kiziltepe

Assistant Professional Specialist

Department of Chemical and Biomolecular Engineering

Assistant Professional Specialist
College of Engineering

Email: tkiziltepe@nd.edu

Phone: 574-631-1603

Office: 105 Cushing Hall

Education

B.S. Chemistry, Bilkent University, Turkey (1998)

Ph.D. Biological Chemistry, Massachusetts Institute of Technology, MA (2004)

Biography

Postdoc Fellow, Dana Farber Cancer Institute, MA (2005-2007)
Faculty, Harvard Medical School, MA (2005-2007)
Scientist, Cerulean Pharmaceuticals, MA (2007-2008)
Assistant Research Professor, University of Notre Dame, IN (2008-present)

Publications

Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Vallet S, Okawa Y, Ikeda H, Ishitsuka K, Shiraishi N, Chauhan D, Anderson KC. 5-Azacytidine, a DNA Methyltransferase Inhibitor, Induces ATR Mediated DNA Double Strand Break Responses, Apoptosis, and Synergistic Cytotoxicity with Doxorubicin and Bortezomib against Multiple Myelo. Mol Cancer Ther., 6(6):1718-27, 2007.

Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GE, Keefer LK, Shami PJ, and Anderson KC. JS -K, a GST-Activated Nitric Oxide Generator, Induces DNA Double Strand Breaks, activates DNA Damage Response Pathways, and Induces Apoptosis, in vitro and in vivo in Human Multiple Myeloma Cells. Blood, 110(2):709-18, 2007.

Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 436(7050):568-72, 2005.

Hideshima T, Chauhan D, Kiziltepe T, Ikeda H, Okawa Y, Podar K, Raje N, Protopopov A, Munshi NC, Richardson PG, Carrasco RD, Anderson KC. Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications.. Blood, 113 (21):5228-36, 2009.

Summary of Activities/Interests

Pre-clinical drug validation in cancers
Nanoparticle based drug delivery
Biochemical stabilization of biomolecular therapeutics

News

Taking Multiple Myeloma Down for the Count

July 7, 2016

When battling cancer, everything is on the table. Radiation therapy. Surgery. Chemo. Advances in nanotechnology have enabled researchers, like Associate Professor Z. Basar Bilgicer, Research Assistant Professor Tanyel Kiziltepe, and their team in the Department of Chemical and Biomolecular Engineering at the University of Notre Dame, to encapsulate cancer-fighting/cancer-killing drugs into nanoparticles that can deliver therapeutic drugs directly to the site of a tumor, effectively avoiding healthy tissue and minimizing adverse reactions.

AD&T Supported Researchers Improve Drug Delivery, Spur Commercial Activity

May 24, 2016

A new cancer fighting technology developed by Basar Bilgicer and Tanyel Kiziltepe, two professors with deep ties to the University of Notre Dame’s Advanced Diagnostics & Therapeutics initiative, is making a rapid and exciting transition to a real-world, commercialized product — one that could increase the effectiveness of cancer medications while lessening their toxic effects and improving patients’ quality of life.

Nanoparticles Engineered at Notre Dame Promise to Improve Blood Cancer Treatment

June 29, 2012

Researchers from the University of Notre Dame have engineered nanoparticles that show great promise for the treatment of multiple myeloma (MM), an incurable cancer of the plasma cells in bone marrow.

Nanoparticles Engineered at Notre Dame Promise to Improve Blood Cancer Treatment

June 19, 2012

Researchers from the University of Notre Dame have engineered nanoparticles that show great promise for the treatment of multiple myeloma (MM), an incurable cancer of the plasma cells in bone marrow.